CS
CRL icon

Candriam SCA’s Charles River Laboratories CRL Stock Holding History

Candriam SCA’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.8M Buy
105,152
+18,722
+22% +$3.33M 0.11% 181
2026
Q1 		$14.9M Buy
86,430
+53,149
+160% +$9.85M 0.08% 227
2025
Q4 		$6.64M Buy
+33,281
New +$6.04M 0.03% 335
2023
Q2 		– Sell
-2,866
Closed -$532K – 760
2023
Q1 		$532K Sell
2,866
-2,287
-44% -$518K ﹤0.01% 765
2022
Q4 		$1.12M Sell
5,153
-46,301
-90% -$10.1M 0.01% 679
2022
Q3 		$10.1M Sell
51,454
-2,353
-4% -$508K 0.07% 269
2022
Q2 		$11.5M Sell
53,807
-13,723
-20% -$3.35M 0.09% 206
2022
Q1 		$19.2M Sell
67,530
-62,879
-48% -$19.4M 0.13% 171
2021
Q4 		$49.1M Sell
130,409
-90,296
-41% -$35.1M 0.31% 77
2021
Q3 		$91.1M Sell
220,705
-17,442
-7% -$7.24M 0.62% 35
2021
Q2 		$88.1M Buy
238,147
+167,967
+239% +$56.1M 0.6% 38
2021
Q1 		$16.8M Buy
70,180
+11
+0% +$3.06K 0.14% 161
2020
Q4 		$17.5M Buy
70,169
+26,323
+60% +$6.27M 0.14% 162
2020
Q3 		$9.93M Buy
+43,846
New +$9.1M 0.09% 238

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Candriam SCA's CRL Position: Q2 2026 in Review

Candriam SCA increased its Charles River Laboratories (CRL) stake by 22% in Q2 2026, buying an estimated $3.33M and bringing the position to 105,152 shares worth $23.8M. The position accounts for 0.11% of the portfolio, ranked #181.

Candriam SCA first reported a position in CRL in Q3 2020 and has held it in 14 quarters since. The position peaked at $91.1M in Q3 2021. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Candriam SCA held 105,152 shares of Charles River Laboratories worth $23.8M as of Q2 2026.
  • Candriam SCA bought 18,722 Charles River Laboratories shares in Q2 2026, an estimated $3.33M.
  • Charles River Laboratories made up 0.11% of Candriam SCA's portfolio in Q2 2026, its #181 holding.
  • Candriam SCA first reported a position in Charles River Laboratories in Q3 2020 and has held it in 14 quarters since.
  • Candriam SCA's Charles River Laboratories position peaked at $91.1M in Q3 2021.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.